Acurx Pharmaceuticals (NASDAQ:ACXP) on Friday reported a full-year 2025 net loss of $8 million, with cash and cash equivalents of $7.6 million as of December 31, 2025, supported by approximately $4 million in gross proceeds from its equity line of credit during the year.
Shares outstanding totaled 2,348,113 at year-end.
The clinical-stage biopharmaceutical company, focused on developing small-molecule antibiotics targeting Gram-positive bacteria, announced plans to initiate an open-label 20-patient pilot study evaluating ibezapolstat in patients with recurrent Clostridioides difficile infection (rCDI), building on prior Phase 2 data.
In the completed Phase 2 trial, ibezapolstat achieved a 96% clinical cure rate across 26 patients with no recurrences observed, demonstrating promising efficacy and safety in the treatment of C. difficile infection.
Meanwhile, Acurx received a new U.S. Patent and Trademark Office patent extending protection for key aspects of its Pol IIIC inhibitor program through December 2039, strengthening intellectual property coverage for its lead candidate and follow-on compounds.
The company also published structural biology data further supporting the mechanism of action of its DNA polymerase IIIC-targeted antibiotics in a peer-reviewed journal.